GHK-Cu Explained: The Copper Peptide Behind Decades of Skin and Tissue Research

GHK-Cu: What the Research Actually Says About the Copper Peptide

Few peptides have a research history as long as GHK-Cu. First identified in the 1970s, it has since appeared in hundreds of studies and in skincare products worldwide. Here's a clear look at what it is, how researchers think it works, and where the evidence stands.

What is GHK-Cu?

GHK-Cu is a small complex made of three amino acids (glycine, histidine and lysine) bound to a copper ion. The tripeptide GHK occurs naturally in human plasma, saliva and urine.

It was first isolated in 1973 by biochemist Dr Loren Pickart, who observed that plasma from younger people affected liver tissue differently from plasma taken from older people. GHK turned out to be one of the factors involved. Its strong attraction to copper is central to how it behaves in the body.

Why age matters in GHK research

Reported plasma levels of GHK fall considerably with age, from roughly 200 ng/mL around age 20 to about 80 ng/mL by age 60. This decline is one reason the peptide attracts attention in longevity and ageing research. A falling level is an observation, though. It doesn't show that the decline causes ageing, or that replacing it would reverse anything.

How researchers think it works

Laboratory and animal studies suggest GHK-Cu acts through several pathways:

• Copper delivery. GHK binds copper and may help transport it to cells in a controlled, non-toxic form. Copper is a cofactor for enzymes involved in connective tissue and antioxidant defence.
• Extracellular matrix activity. In cell-culture studies, GHK-Cu has been linked to increased production of collagen, elastin and glycosaminoglycans by fibroblasts, and to regulation of the enzymes that break down and remodel tissue.
• Gene expression. Analyses using the Broad Institute's Connectivity Map indicated that GHK may influence the expression of a large number of human genes, including some related to tissue repair and inflammation. These are computational and in-vitro findings, not clinical outcomes.
• Antioxidant and anti-inflammatory signalling. Several studies report reduced markers of oxidative stress and inflammation in lab models.

Areas of study

Skin. This is the most established area. GHK-Cu has been used in cosmetic formulations for decades, and small human studies of topical products have reported improvements in measures such as skin density, firmness and the appearance of fine lines.

Wound healing. Animal studies from the 1980s onward examined GHK-Cu in wound models, which is where much of the early interest came from.

Hair. Some lab and small-scale studies have looked at copper peptides and hair follicle size.

What the evidence doesn't show

It's worth being clear about the limits:

• Most data comes from cell cultures, animal models and small cosmetic trials.
• There are no large, independent clinical trials establishing GHK-Cu as a treatment for any medical condition.
• It is not an authorised medicinal product in Ireland or the EU.

Anyone reading claims online that go beyond this should treat them with caution.

Key references

• Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018.
• Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition, 2008.

---

This article is for educational and informational purposes only. It does not constitute medical advice, and nothing here is intended to diagnose, treat, cure or prevent any disease. Consult a qualified healthcare professional with any health questions.